Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have earned a consensus rating of “Hold” from the nine analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.67.
A number of equities research analysts have recently weighed in on OCUL shares. Piper Jaffray Companies dropped their price objective on Ocular Therapeutix to $8.00 and set a “market perform” rating for the company in a research note on Monday, May 20th. Zacks Investment Research raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. HC Wainwright dropped their price objective on Ocular Therapeutix from $12.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday. Cowen cut Ocular Therapeutix from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $13.00 to $3.00 in a research note on Tuesday. Finally, ValuEngine cut Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st.
In related news, Director Richard L. Md Lindstrom bought 56,441 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was purchased at an average cost of $4.33 per share, for a total transaction of $244,389.53. Following the completion of the acquisition, the director now owns 100,000 shares in the company, valued at approximately $433,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael H. Goldstein bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was bought at an average price of $4.15 per share, with a total value of $41,500.00. The disclosure for this purchase can be found here. Insiders bought 90,441 shares of company stock valued at $385,490 over the last ninety days. Insiders own 16.10% of the company’s stock.
OCUL stock traded up $0.18 during midday trading on Monday, hitting $2.64. 896,505 shares of the company’s stock were exchanged, compared to its average volume of 544,770. The company has a quick ratio of 9.16, a current ratio of 9.19 and a debt-to-equity ratio of 2.17. The stock has a market cap of $113.09 million, a price-to-earnings ratio of -1.68 and a beta of 1.80. Ocular Therapeutix has a 1-year low of $2.35 and a 1-year high of $8.28.
Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The business had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.45 million. Ocular Therapeutix had a negative return on equity of 165.85% and a negative net margin of 2,956.91%. As a group, sell-side analysts anticipate that Ocular Therapeutix will post -1.42 EPS for the current year.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.
Read More: What is Call Option Volume?
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.